A New Hope for CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases

Catherine S. Forconi\textsuperscript{1†}, Cliff I. Oduor\textsuperscript{2,3†}, Peter O. Oluoch\textsuperscript{1,3}, John M. Ong’echa\textsuperscript{3}, Christian Münz\textsuperscript{4}, Jeffrey A. Bailey\textsuperscript{2} and Ann M. Moormann\textsuperscript{1∗}

\textsuperscript{1} Division of Infectious Diseases, Department of Medicine, University of Massachusetts, Worcester, MA, United States, \textsuperscript{2} Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI, United States, \textsuperscript{3} Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya, \textsuperscript{4} Laboratory of Viral Immunology, Experimental Immunology Institute, University of Zurich, Zurich, Switzerland

Natural Killer (NK) cells play an essential role in antiviral and anti-tumoral immune responses. In peripheral blood, NK cells are commonly classified into two major subsets: CD56\textsuperscript{bright}CD16\textsuperscript{neg} and CD56\textsuperscript{dim}CD16\textsuperscript{pos} despite the characterization of a CD56\textsuperscript{neg}CD16\textsuperscript{pos} subset 25 years ago. Since then, several studies have described the prevalence of an CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cell subset in viral non-controllers as the basis for their NK cell dysfunction. However, the mechanistic basis for their cytotoxic impairment is unclear. Recently, using a strict flow cytometry gating strategy to exclude monocytes, we reported an accumulation of CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells in Plasmodium falciparum malaria-exposed children and pediatric cancer patients diagnosed with endemic Burkitt lymphoma (eBL). Here, we use live-sorted cells, histological staining, bulk RNA-sequencing and flow cytometry to confirm that this CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cell subset has the same morphological features as the other NK cell subsets and a similar transcriptional profile compared to CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells with only 120 genes differentially expressed (fold change of 1.5, \(p < 0.01\) and FDR\textless 0.05) out of 9235 transcripts. CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells have a distinct profile with significantly higher expression of MPEG1 (perforin 2), FCGR3B (CD16b), FCGR2A, and FCGR2B (CD32A and B) as well as CD6, CD84, HLA-DR, LILRB1/2, and PDCD1 (PD-1), whereas Interleukin 18 (IL18) receptor genes (IL18RAP and IL18R1), cytotoxic genes such as KLRF1 (NKp80) and NCR1 (NKp46), and inhibitory HAVCR2 (TIM-3) are significantly down-regulated compared to CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. Together, these data confirm that CD56\textsuperscript{neg}CD16\textsuperscript{pos} cells are legitimate NK cells, yet their transcriptional and protein expression profiles suggest their cytotoxic potential is mediated by pathways reliant on antibodies such as antibody-dependent cell cytotoxicity (ADCC), antibody-dependent respiratory burst (ADRB), and enhanced by complement receptor 3 (CR3) and FAS/FASL interaction. Our findings support the premise that chronic diseases induce NK cell...
INTRODUCTION

Natural Killer (NK) cells are crucial mediators of innate immune responses against virally infected and malignant cells (Herberman et al., 1975; Kiessling et al., 1975; Trinchieri and Santoli, 1978). NK cell function depends on a balance between activation and inhibition signals triggered by multiple surface receptors engaged during their surveillance of host cells (Long et al., 2013). NK cells were originally defined as CD3negCD56pos cells and represent 10 to 15% of lymphocytes in peripheral blood (Robertson and Ritz, 1990). CD56 is a Neural Cell Adhesion Molecule 1 (NCAM-1) involved in cell-to-cell and cell-to-matrix interactions (Lanier et al., 1991) and its expression varies with NK cell maturation. Of the peripheral NK cells, ~10% are CD56bright NK cells which are essential for pro-inflammatory cytokine production (Cooper et al., 2001) particularly when they also express CD62L, an adhesion/homing molecule (Cichocki et al., 2016) and are less cytotoxic (Jacobs et al., 2001); whereas CD56dim NK cells comprise ~90% of NK cells in healthy adults and have low cytokine production but high cytotoxic capacity (Cooper et al., 2001; Jacobs et al., 2001). CD56dim NK cells are multifunctional and play either an immunoregulatory role as canonical CD56dim NK cells characterized as CD62LnegCD57pos Eomesoderminpos (Eomes) Promyelocytic Leukemia Zinc Fingerpos (PLZF) (Cichocki et al., 2016) or are considered adaptive NK cells which do not express PLZF or FcRγ (also referred to as an Immunoreceptor Tyrosine-based Activation Motif (ITAM)-bearing transmembrane adapter protein). Adaptive NK cells are involved in immunosurveillance with induction of cytotoxic granules (perforin and granzymes) upon engagement with CD16, NKG2C or activating Killer Immunosuppressor-like Receptor (KIR) (Hwang et al., 2012; Schlums et al., 2015; Tesi et al., 2016). Recently, adaptive CD56dim NK cells were associated with protection from Plasmodium falciparum (Pf) malaria (Hart et al., 2019). Pf-exposed individual had a higher frequency of FcRγneg CD56dim NK cells and displayed increased antibody-dependent cellular cytotoxicity (ADCC) against Pf-infected red blood cells (Hart et al., 2019).

CD56negCD16pos NK cells were discovered 25 years ago in Human Immunodeficiency Virus (HIV) patients (Hu et al., 1995) and has been shown to expand during other chronic infections, such as Hepatitis C Virus (HCV), especially those who failed treatment (Mavilio et al., 2003, 2005; Gonzalez et al., 2009; Prada et al., 2013) and more recently in human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) co-infected elderly individuals (>60 years of age) (Müller-Durovic et al., 2019). Compared to CD56pos NK cells, CD56neg NK cells have been portrayed as “dysfunctional” because of lower expression of cytotoxic receptors such as Nkp46 and Nkp30, low cytokine production as well as reduction of natural cytotoxicity (Mavilio et al., 2005; Müller-Durovic et al., 2019). More recently, we reported a dramatic expansion of CD56negCD16pos NK cells in African children chronically/repeatedly infected with Plasmodium falciparum malaria and in those who were diagnosed with endemic Burkitt lymphoma (eBL) (Forconi et al., 2018). Proteomic analyses showed similarities between CD56dimCD16pos and CD56negCD16pos NK cells (Voigt et al., 2018) thus supporting the classification of this subset as NK cells. Since CD56negCD16pos NK cells are extremely low in American/European healthy adults (Supplemental Figure 1), most studies have focused on characterizing the function and therapeutic potential of CD56bright and CD56dim NK cell subsets. However, it appears that healthy adults from western Kenya also have a significant proportion of CD56negCD16pos NK cells, similar to children chronically/repeatedly infected with Pf-malaria (Supplemental Figure 1). Besides the emerging evidence associating this NK cell subset with chronic infections, the development and function of CD56negCD16pos NK cells have only begun to be explored.

Endemic BL is an Epstein-Barr virus (EBV) associated, aggressive pediatric cancer that occurs in regions of equatorial Africa with high P. falciparum transmission, i.e., holoendemic malaria (Burkitt, 1962). EBV is a herpesvirus which has evolved to evade immune clearance in order to establish a life-long, asymptomatic infection within immunocompetent individuals (Schmiedel and Mandelboim, 2017). Children residing in malaria holoendemic areas, where eBL incidence is high, are usually infected by EBV before 2 years of age (Piriou et al., 2012). At the same time these children are repeatedly infected with P. falciparum which in turn induces episodes of viral reactivation resulting in higher EBV loads (Moormann et al., 2005; Piriou et al., 2012; Reynaldi et al., 2015). P. falciparum malaria is postulated to diminish EBV-specific immune surveillance as a component of eBL etiology, a cancer common in children aged 5–9 years (Moss et al., 1983; Whittle et al., 1984; Moormann et al., 2007, 2009; Njie et al., 2009; Snider et al., 2012; Chattopadhyay et al., 2013; Parsons et al., 2016). NK cells have been independently shown to help control both of these infections, killing EBV-infected B cells during adolescent acute infectious mononucleosis (AIM) (Azzi et al., 2014) and malaria-infected red blood cells (Horowitz et al., 2010; Wolf et al., 2017). However, little is known about NK cell function during EBV...
and malaria co-infections and their role in protection against eBL pathogenesis. In order to further clarify similarities and differences between CD56dimCD16pos and CD56brightCD16pos NK cells we performed histology staining, bulk RNA sequencing and protein expression profile validation by flow cytometry using fluorescence-activated cell sorting (FACS) of NK subsets of peripheral blood mononuclear cells (PBMCs) isolated from children who had lifelong exposure to *P. falciparum* infections and were diagnosed with eBL.

**METHODS**

**Study Population and Ethical Approvals**

Ethical approval was obtained from the Scientific and Ethics Review Unit (SERU) at the Kenya Medical Research Institute (KEMRI) and the Institutional Review Board at the University of Massachusetts Medical School, Worcester, USA. Written informed consent was obtained from adults and from parents of minor study participants. Healthy children and adults were recruited at a rural health center in Kenya. Inclusion criteria for children were EBV sero-positivity, HIV-negative and born to HIV-negative mothers. Inclusion criteria for Kenyan and American adults was HIV-negative status. Children with suspected eBL were enrolled at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kisumu, Kenya. Two independent pathologists confirmed diagnosis by cytology-pathology and May-Grünwald Giemsa staining. Tumor samples were further characterized by transcriptome and mutational profiling to confirm eBL diagnosis (Kaymaz et al., 2017). This cancer is more prevalent in male compared to female children, with a peak-age incidence ranging from 5 to 9 years old (Buckle et al., 2016), and at the time of this study, we only had sufficient samples from male eBL children. Therefore, baseline peripheral blood samples were used from 8 male eBL children before induction of chemotherapy. However, we have previously shown that both male and female eBL patients have significantly elevated frequencies of CD56brightCD16pos NK cells (Forconi et al., 2018).

**ddPCR to Quantify EBV Load**

For each patient, 500 μl of blood was collected in an EDTA microtainer tube. After 5 min of centrifugation, 200 μl of plasma was separated from the blood cell pellet and replaced by an equivalent amount of 1X PBS, pH 7.4. Using the whole blood DNA extraction kit from Qiagen, DNA was isolated from the PBS resuspended blood cell pellet and total DNA concentration was measured by NanoDrop (Thermo Fisher Scientific). We used digital droplet PCR (ddPCR) to determine EBV load in each sample by amplifying EBV BALF5 and human β-actin gene, using primers and probes shown in Table 1. The duplex ddPCR reactions were prepared in a total volume of 20 μl which contained 10 μl of ddPCR Supermix for probes (No UTP) (Bio-Rad Laboratories), and 2 sets of each primer and probe combination (0.9 μM of primers and 0.25 μM of probes). The BioRad Automated Droplet Generator (AutoDG) (Bio-Rad Laboratories) was used to ensure consistent droplet generation. After the ddPCR reaction, the number of positive and negative droplets were counted by the Bio-Rad QX200TM Droplet reader and EBV viral loads quantified as copies/ng human DNA.

**Multiplex Suspension Bead-Based Serology Assay**

To measure IgG antibody levels in the plasma fraction, we used a Luminex bead-based suspension assay as previously published (Cham et al., 2009; Forconi et al., 2018). In brief, antibodies to Viral Capsid Antigen (VCA) and Epstein-Barr nuclear antigen 1 (EBNA1) (gift from Jaap Middeldorp, Cyto-Barr) were used to determine EBV seropositivity (Middeldorp and Herbrink, 1988; van Grunsven et al., 1994). Previous *P. falciparum* exposure was determined using recombinant proteins to blood stage malaria antigens: apical membrane antigen 1 (AMA1) and merozoite surface protein (MSP1) (gifts from Sheeti Dutta, Evelina Angov, and Elke Bergmann from the Walter Reed Army Institute of Research). Briefly, 200 μg of each antigen or bovine serum albumin (BSA) (Sigma-Aldrich) were coupled to carboxylated beads microspheres (BioRad) and then incubated with plasma samples from our study participants, followed by incubation with biotinylated anti-human IgG diluted 1:1000 and streptavidin (BD Pharmingen) diluted 1:1000 following manufacturer's instructions. Antigen-specific fluorescence values were quantified on a BioPlex 200 multi-analyte analyzer with subtraction of fluorescence values obtained with BSA-conjugated beads for each patient. Results are reported as median fluorescence intensity (MFI) after acquisition of a minimum of 50 beads per antigen.

**Fluorescence-Activated Cell Sorting (FACS) of NK Subsets**

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation and cryopreserved until use (viability > 97%). PBMCs were thawed at 37°C in complete media composed of RPMI, 10% heat-inactivated Fetal Bovine Serum (MilliporeSigma), 2 mM L-glutamine, 1X Penicillin/Streptomycin and 10 mM HEPES (Invitrogen). NK cell subsets were then isolated using a 16-color BD FACS 2-ARIA II cell sorter at the UMASS Flow Cytometry Core. The gating strategy (Figure 1) used the following antibody/fluorochrome combinations identified by the Resource Identification Portal number RRID to isolate NK subsets: CD16-BV510 (RRID: AB_2562085) and CD56-PECy7 (RRID: AB_399970) with the

| **TABLE 1** | Droplet Digital PCR (ddPCR) EBV and Human Primer and Probe Sequences. |
|-------------|---------------------------------------------------------------------|
| **Sequence 5′-3′** | **EBV-BALF5 FP** | **EBV-BALF5 RP** | **EBV-BALF5 Probe** | **Human β-actin FP** | **Human β-actin RP** | **Human β-actin Probe** |
| **FP** | GAAAGCCCTCTGAGCTCATG | CCCTGTTATCCATGGATGAT | FAM -TGTAAGTCGACGAGAAATGCGCT -BHQ-1 | GCTCATGCGAAGAAGTGGCTC | GCAAAGGTTGCCCTTGAAGGT | HEX-AGTGATGGCCTGGCCTCACCTGGAC-BHQ |
| **RP** | GCTCATGGCAAGAAAGTGCTC | GAAGCCCTCTGAGCTCATG | GAAAGCCCTCTGAGCTCATG | GCTCATGCGAAGAAGTGGCTC | GCAAAGGTTGCCCTTGAAGGT | HEX-AGTGATGGCCTGGCCTCACCTGGAC-BHQ |

FP, Forward primer; RP, Reverse primer.
Forconi et al. New Hope for CD56negCD16pos NK Cells

FIGURE 1 | Gating strategy for FACS and HandE staining. PMBCs were gated on (A) lymphocytes size determined by SSC-A vs. FSC-A cytplots, then (B) live, and (C) single cells were selected. (D) A Dump channel was used to eliminate CD3+, CD14+, and CD19+ cells. These cells were stained purple using hematoxylin and eosin (HandE), as shown in photo 1. Then (D) CD3–CD14+CD19- cells were (E) sorted based on CD56 vs. CD16 expression and the three isolated NK cell subsets were stained with HandE: photo 2 CD56brightCD16neg, photo 3 CD56dimCD16pos, and photo 4 CD56negCD16pos.

exclusion of dead cells by 7’AAD (BD Pharmingen, Cat#559925) and dump channel for cells expressing either CD3-BV421 (RRID: AB_10962690), CD14-BV421 (RRID: AB_2563296), or CD19-BV421 (RRID: AB_11142678). In order to compare cell morphology between CD56dimCD16pos and CD56negCD16pos NK cell subsets, we also collected the CD56brightCD16neg NK cells and CD3+CD14+CD19+ cells.

Morphology by Light Microscopy
To examine morphology, live-sorted cells from each subset were cytospun on a slide and stained with hematoxylin and eosin (H&E) following Hema 3TM Stat Pack kit instructions (Fisherbrand Cat#122-911). Hematoxylin stains the nucleus deep blue-violet whereas eosin stains the elastin/collagen/reticular fibers of the cell pink. Slides were imaged on Nikon microscope Eclipse E400 with ocular lens 10x and 100x objectives using the DS-Qi1MC and Digital Sight DS-U3 (Nikon) camera system and NIS-Element BR version 4.20 software. Images were analyzed by a clinical pathologist and transfusion specialist at UMass Medical School to determine cell types.

RNA Sequencing
Live-FACS sorted NK cell subsets (CD56dimCD16pos and CD56negCD16pos) were immediately collected in 4°C 2× Buffer TCL with (2%) β-mercaptoethanol (Qiagen). Total RNA was isolated and strand-specific ribosomal RNA-depleted sequencing libraries were generated using the standard protocol of SMARTer Stranded Total RNA-Seqv2 Pico input kit (Takara Bio). Given the small quantity of total RNA that was obtained from the ~5,000 NK cells sorted for each subset, the depletion of abundant rRNA was performed after cDNA synthesis using probes specific to mammalian rRNA. Sequencing libraries were purified using XP Ampure magnetic beads (Beckman Coulter Inc.) after each reaction step. Final libraries were amplified using SeqAmp DNA polymerase, and qualities and concentrations were measured with a Bioanalyzer Agilent High sensitivity DNA kit. Samples were sequenced on an Illumina HiSeq 4000 (Illumina, Inc.), obtaining depths of 10–20 million paired-end 50 bp reads for each NK cell subset sequenced. Sequencing files were deposited in the NCBI’s database of Genotypes and Phenotypes (dbGaP) with accession number phs001282.v2.p1.

Differential Gene Expression Analysis
Differential gene expression was performed using standard methods. Sequence reads were first checked for quality using FastQC (Andrews, 2014) and sorted by sample based on the unique sample indexes identified by Novobarcode (Novocraft Technologies). Residual Illumina 3’-end adaptor sequences and
template switching oligos introduced during the cDNA synthesis were trimmed using Cutadapt (Martin, 2011). Paired reads were then aligned to a transcriptome index built by RNA-Seq by expectation-maximization (RSEM) (Li and Dewey, 2011) using Gene code annotation version 19 for protein coding transcripts and hg19 genomic sequence. RSEM calculated strand-specific expected read counts for each gene and gene expression count matrices for each NK cell subset were generated for downstream statistical analyses that were performed with R software (https://www.R-project.org/) (version 3.5.3).

Differential gene expression analysis between NK cell subsets (CD56dimCD16pos and CD56negCD16pos) was performed using R package edgeR (Robinson et al., 2010) which implements a Trimmed mean of M-values (TMM) normalization and a negative binomial approach (Robinson and Oshlack, 2010). We removed from the analysis all genes for which all counts per million (CPM) values were lower than 5 cpm. To control multiple testing, we applied the Benjamini-Hochberg procedure (BH) with threshold for statistical significance set at an adjusted p-value < 0.01 and false discovery rate (FDR) < 0.05.

Validation by Flow Cytometry
PBMCs from 3 eBL children (2 of them were also used for RNA-sequencing) and 3 healthy Kenyan children were thawed and FACS live-sorted, as described above. In addition, we included the following antibodies: CD62L-PerCP5.5 (RRID: AB_2239105), DNAM1-BV711 (RRID: AB_2738956), TIM3-BV60 (RRID: AB_2565829), PD-1-APC-Fire750 (RRID: AB_2616721) and granzyyme B-APC (RRID: AB_1500190); CD32-PerCP5.5 (RRID: AB_2616924) and IL18Ra-APC (RRID: AB_2616721) and stained by H&E in order to assess their morphology. The genes identified to be significantly differentially expressed (p-value < 0.01 and FDR < 0.05) between the NK cell subsets were further analyzed using the gProfiler software (https://biit.cs.ut.ee/gprofiler) (Raudvere et al., 2019) to explore the potential functional consequences and associated pathways. gProfiler was run using g:GOSt ordered query with Bonferroni correction and a threshold of 0.01 equating to a p-unadjusted < 10.E-16.

RESULTS
Characterization of the Samples
Initial samples at diagnosis prior to chemotherapy from 8 eBL children were used for this study with a median age of 9.5 years (Table 2). Serology for the two pathogens associated with eBL was assessed and all children were seropositive for both EBV and P. falciparum. Survival outcomes varied with five eBL children (62%) being long-term (>2 year) survivors and three (38%) in-hospital deaths. Half of the children had low EBV loads (median 0.5 EBV copies/ng of human DNA) and half had high EBV loads (median 23.3 copies/ng of human DNA). No child in our study had lymphopenia with a median absolute lymphocyte count (ALC) of 3.5 x 10^3 lymphocytes per μl blood (Shapiro et al., 1998). Finally, the percentage of each NK subset was assessed within the total NK cell population. Consistent with our previous study (Forconi et al., 2018), eBL children had elevated CD56neg CD16pos NK cell subset, with a median of 30.3%.

Morphology of CD56negCD16pos Cells Similar to Other NK Subsets
After live-sorting, an aliquot of each cell subset was fixed and stained by H&E in order to assess their morphology (Figure 1). All three NK cell subsets CD56brightCD16neg (Figure 1, photo 2), CD56dimCD16pos (Figure 1, photo 3) and CD56negCD16pos (Figure 1, photo 4) had similar morphology by microscopy, round in shape, ~10 μm in size and with a prominent nucleus typical of lymphocyte histology. Importantly, these cells differed morphologically compared to CD14+ monocytes (Figure 1, photo 1), which were larger (averaging 15–18 μm in diameter), ameboid in appearance, had a lighter cytoplasm, and unilobar nucleus. This morphological comparison confirms that CD56negCD16pos NK cells are visually indistinguishable from other NK cell subsets and are clearly not monocytes.

### Table 2 | Patients characteristics.

| Characteristic          | eBL (n = 8)          |
|-------------------------|----------------------|
| Age†                   | 9.5 [6.5–11.75]      |
| Sex (Male)             | 8                    |
| Hemoglobin (g/dl)†     | 10.80 [9.75–11.55]   |
| ALC (x10^3 lymphocytes per μl)† | 346.8 [214.1–418.4] |
| Serology in Median Fluorescence | 8,848 [6,595–24,668] |
| Intensity (MFI): EBNA1† |                      |
| VCA†                   | 28,114 [15,487–31,459] |
| MSP-1 (3D7)†           | 27,785 [22,058–29,767] |
| AMA-1†                 | 26302 [21,173–31,008] |
| Survivors:             | 5 (82%)              |
| Non-survivors:         | 3 (38%)              |
| Low EBV viral load:    | 0.5 [0.11–0.7]       |
| High EBV viral load:   | 23.35 [7.47–245.1]   |
| Tumor localization     |                      |
| Jaw:                   | 3 (38%)              |
| Abdomen:               | 5 (82%)              |
| % CD56dim within NK cells: | 56.6 [34.55–67.1] |
| % CD56neg within NK cells: | 30.30 [24.23–57.1] |

† Median [25–75% interquartile].
Validating the Purity of Sorted NK Cell Subsets

To check the purity of the sorted CD56<sup>dim</sup>CD16<sup>pos</sup> and CD56<sup>neg</sup>CD16<sup>pos</sup> NK cell subsets, we explored the normalized expression values [transcripts per million (TPM)] of each gene, to assess if any of the classical monocyte or neutrophil gene signatures were detected on the bulk RNA-sequencing data of the sorted cells. From this interrogation, we identified one of the CD56<sup>neg</sup>CD16<sup>pos</sup> NK samples as having higher expression of classical monocyte genes (CD14 and CD33) (Supplemental Figure 2), suggestive of trace monocyte contamination. Thus, this sample was excluded from further analysis leaving us with 7 CD56<sup>neg</sup>CD16<sup>pos</sup> and 7 CD56<sup>dim</sup>CD16<sup>pos</sup> NK subsets for downstream differential expression analysis. All remaining samples lacked expression of CD14, CD33, and CD34 (Supplemental Figure 3A). In addition, we found that neither NK cell subset expressed neutrophil-associated genes, such as CD66b (CEACAM8), ARG1, MPO, ABCA13, CA1, IFTT1B, CRISP3, LCN2, BPI, CNTNAP3B, and PAD4 (Supplemental Figure 3B).

Moreover, other neutrophil-associated genes, such as the integrin family genes ITGAL (CD11a), ITGAM (CD11b), ITGAD (CD11d), and ITGB2 (CD18) which are involved in innate immunity (Roberts et al., 2016) and can be expressed by NK cells were observed in both the CD56<sup>dim</sup>CD16<sup>pos</sup> and CD56<sup>neg</sup>CD16<sup>pos</sup> NK cell subsets (Supplemental Figure 3B). In addition, we show that PTPRC (CD45) was highly expressed in both the CD56<sup>neg</sup>CD16<sup>pos</sup> and CD56<sup>dim</sup>CD16<sup>pos</sup> NK cell subsets (logCPM = 11.37, Figure 2). CD45 is known to be expressed on hematopoietic cells and more highly expressed on lymphoid cells compared to myeloid cells based on BioGPS and MyGene.info organizing online gene-centric information (Wu et al., 2013). This criteria further supports the premise that CD56<sup>neg</sup>CD16<sup>pos</sup> cells are lymphocytes.

CD56<sup>neg</sup>CD16<sup>pos</sup> and CD56<sup>dim</sup>CD16<sup>pos</sup> NK Cells Transcriptome Expression Profiles

Using purified CD56<sup>dim</sup>CD16<sup>pos</sup> and CD56<sup>neg</sup>CD16<sup>pos</sup> NK cell subsets we compared their gene expression profiles and identified 536 genes that were differentially expressed (p-value<0.01 and FDR 0.05) among a combined total of 9,235 genes (Supplemental Figure 4, Suplemental Table 1). Of the differentially expressed genes, 120 had a log Fold Change (logFC) >1.5, with 73 genes downregulated and 47 genes upregulated in CD56<sup>neg</sup>CD16<sup>pos</sup> relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells. Each sample showed appropriate expression based on their flow sorting: CD56<sup>dim</sup>CD16<sup>pos</sup> vs. CD56<sup>neg</sup>CD16<sup>pos</sup> suggesting minimal cross-contamination. To further characterize the CD56<sup>neg</sup>CD16<sup>pos</sup> cell subset, we examined the expression of genes that define and distinguish NK cells from other cell types (Figures 2A,B, and Supplemental Table 1). Innate Lymphoid Cells (ILCs) have been categorized into 5 Groups: NK cells that differ based on developmental trajectories from ILC of Group 1 (ILC1) yet both display type 1 immunity, Group 2 (ILC2) able to produce type 2 cytokines, Group 3 (ILC3) defined by their capacity to produce IL-17A and IL-22 and lymphoid tissue-inducer cells (LTi) involved in the creation of secondary lymphoid organ (Vivier et al., 2018). ILC2s are also defined by their expression of GATA3, BCL11B, and GFI1 which we found to be expressed at similar levels within CD56<sup>neg</sup>CD16<sup>pos</sup> relative to the CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells (Figure 2C). However, amphiregulin (AREG) which is expressed by ILC2 group, appeared slightly downregulated in CD56<sup>neg</sup>CD16<sup>pos</sup> relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells (logFC of −1.32, p-value = 2.24E-06 and FDR of 0.001). Regarding ILC3 genes, AHR was similarly expressed in both NK cell subsets but neither CD56<sup>neg</sup>CD16<sup>pos</sup> nor CD56<sup>dim</sup>CD16<sup>pos</sup> cells expressed CSF2 and RORC, considered classical ILC3 genes. Together, the transcriptional profile for CD56<sup>neg</sup>CD16<sup>pos</sup> cells conform to neither Group 2 nor 3.

CD56<sup>neg</sup>CD16<sup>pos</sup> NK Cells Display a Transcriptome Signature Reminiscent of Adaptive NK Cells

Even though 98.7% of genes shared expression between the two NK cell subsets, the differentially expressed genes shed light on functional differences between these two cell populations. Applying our NK-centric transcriptomic analysis, we show that both CD56<sup>neg</sup>CD16<sup>pos</sup> and CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells express activation and maturation markers such as KLRD1 (CD94), CD96, and B3GAT1 (CD57) (Figure 2B). However, CD56<sup>neg</sup>CD16<sup>pos</sup> NK cells had lower expression of CLEC2C (CD69, logFC of −1.45, p-value = 3.96E-10 and FDR of 7.06E-08) and CD38 (log CPM of 7.47 with logFC of −0.53, p-value = 0.0005 and FDR of 0.014) relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cell. In contrast, CD56<sup>neg</sup>CD16<sup>pos</sup> NK cells tend to express more HLA-DRA (logCPM of 5.78 with logFC of 0.91, p-value = 0.001 and FDR of 0.03) and CD6 (logCPM of 6.32 with logFC of 0.96, p = 4.84E-06 and FDR of 0.0002) relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cell. As expected, NCAM-1 (CD56) was strongly downregulated in CD56<sup>neg</sup>CD16<sup>pos</sup> cells compared to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells (logFC of −5.84, p-value = 2.17E-198 and FDR of 2.03E-194). Regarding their ability to proliferate, MKI67 (Ki67) was not differentially expressed (logFC of 0.42, p-value = 0.18) between the two subsets. Although, we observed higher expression of SPI1 (PU1, logFC of 2.65, p-value = 0.0002 and FDR of 0.006) for the CD56<sup>neg</sup>CD16<sup>pos</sup> relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells. SPI1 has been suggested to play a role in NK cell proliferation (Sun, 2016).

Besides potential cytotoxic and pro-inflammatory functions, NK cells have been implicated in regulating immunity by killing activated T cells or antigen-presenting cells (Ferlazzo et al., 2002; Waggner et al., 2011; Crouse et al., 2014). Therefore, we queried the CD56<sup>neg</sup>CD16<sup>pos</sup> NK cell transcriptome for immunoregulatory cytotoxic activity. Interestingly,SELL (CD62L, logFC of −3.08, p-value = 9.28E-17 and FDR of 1.09E-13) and ZBTB16 (PLZF, logFC of −2.52, p-value = 2.65E-14 and FDR of 1.24E-11) gene expression was significantly lower in CD56<sup>neg</sup>CD16<sup>pos</sup> relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells, and both ITGA9 (CD103) and ITGAV (CD49a) were not expressed which suggests that CD56<sup>neg</sup>CD16<sup>pos</sup> cells may be a form of adaptive NK cell. This is consistent with
FIGURE 2 | Continued
CD56<sup>-</sup>CD16<sup>pos</sup> NK Cells Express Higher Levels of PDCD1 and LILR Family Inhibitory Receptors Relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK Cells

To evaluate the therapeutic potential of these two NK cell subsets, we examined the expression of common NK cell inhibitory molecules (Figure 2B). Most of the KIR members, TIGIT and LAIR1 were similarly expressed by CD56<sup>-</sup>CD16<sup>pos</sup> and CD56<sup>dim</sup>CD16<sup>pos</sup> cells. But interestingly, CD56<sup>-</sup>CD16<sup>pos</sup> NK cells expressed significantly lower KLRG1 (logFC of −1.48) and KLRB1 (CD161, logFC of −2.43) compared to the CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells, whereas KLRB1 (CD161) was downregulated in CD56<sup>-</sup>CD16<sup>pos</sup> NK cells. In contrast, PDCD1 (PD-1, logFC of 2.26) and LILR family members, LILRB1 (logFC of 1.21) and LILRB2 (logFC of 3.35) were observed to be upregulated within CD56<sup>-</sup>CD16<sup>pos</sup> compared to CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells. However, PDCD1 was weakly expressed within CD56<sup>-</sup>CD16<sup>pos</sup> cells (logCPM of 4) compared to higher expression of LILRB1 (logCPM of 6). Together these data suggest that CD56<sup>-</sup>CD16<sup>pos</sup> NK cells are not exhausted but do overexpress distinct inhibitory receptors that may pose a challenge to overcome with NK-based immune checkpoint inhibitors.

### CD56<sup>-</sup>CD16<sup>pos</sup> NK Cells Express Low NKp80 & NKp46 but High CD16, CD32 and Perforin Relative to CD56<sup>dim</sup>CD16<sup>pos</sup> NK Cells

We previously showed that CD56<sup>-</sup>CD16<sup>pos</sup> NK cells were poorly cytotoxic in K562 co-culture assays (Forconi et al., 2018), however at the transcriptional level we observed similar gene expression of some activation (KLR2/NKG2C, SLAMF7/CRAAC, TRAIL, CRTAM/CRTAM), co-stimulation (CD244/2B4, KLRK1/NKG2D) and natural cytotoxic receptors (NCR3/NKP30) for these two subsets (Figure 2B). Yet, CD56<sup>-</sup>CD16<sup>pos</sup> NK cells expressed less KLRF1 that codes for the natural cytotoxic receptor NKp80 (logFC−3.14, p-value = 6.02E-16 and FDR of 4.03E-13), NCR1 (NKP46, logFC−1.25, p-value = 1.13E-09 and FDR of 1.63E-07), CD226 (DNAM-1, logFC−1.55, p-value = 1.66E-11 and FDR of 4.39E-09) and CD160 (logFC−1.11, p-value = 1.72E-08 and FDR of 1.87E-06) which might explain in part the loss of cytotoxicity against K562 cells along with the absence of the CD56 adhesion molecule. In contrast, FCGR3A (CD16a) is highly expressed on both CD56<sup>+/-</sup>CD16<sup>pos</sup> NK cells (logCPM of 9.81) and CD56<sup>dim</sup>CD16<sup>pos</sup> NK cells. CD56<sup>-</sup>CD16<sup>pos</sup> NK cells expressed higher levels of FCGR3B (CD16b) (logFC of 2.03, p-value = 0.0005 and FDR of 0.013), FCGR2A (CD32A, logFC of 1.4,
p-value = 3.69E-10 and FDR of 6.78E-08), and FCGR2B (CD32B, logFC of 1.06, p-value = 7.68E-07 and FDR of 5.25E-05) relative to CD56dimCD16pos NK cells with a slightly elevated expression of CD84 (logCPM of 6.47, logFC of 0.76, p-value = 4.07E-05 and FDR of 0.001), respectively. We were surprised to see significantly elevated expression of cytotoxic molecules such as MPEG1 (perforin 2) for the CD56negCD16pos compared to CD56dimCD16pos NK cells (logFC of 3.55, p-value = 1.44E-07 and FDR of 1.25E-05). Despite this interesting observation, other genes involved in direct cytotoxicity, such as LYZ (lysozyme), LAMP-1 (CD107a), FASLG (FAS-L), GZMH and GZMM (granzyne H and M) were not differentially expressed between the CD56negCD16pos and CD56dimCD16pos NK cells, supporting their ability to kill target cells by degranulation and through the FAS-L/FAS pathway. CD56negCD16pos NK cells expressed PRFI (perforin 1, logCPM of 10.54, logFC of −0.62), GZMA (granzyme A, logCPM of 8.06, logFC of −0.75) and GZMB (granzyne B, logCPM of 9.15, logFC of −0.8) these markers were slightly lower for CD56negCD16pos compared to CD56dimCD16pos NK cells. Another gene related to cytotoxicity GNLY (granulysin or LG2) was significantly downregulated in CD56negCD16pos relative to CD56dimCD16pos NK cells (logCPM of 9.83 and logFC of −2.27). Overall, these data suggest that CD56negCD16pos NK cells retain cytotoxic potential, albeit mediated through different mechanisms compared to CD56dimCD16pos NK cells.

CD56negCD16pos NK Cells Express Less IL-2, IL-12, and IL-18 Receptors Relative to CD56dimCD16pos NK Cells

As shown in Figure 2B, we found no differences in IL2RG gene expression (subunit γ of the IL2 receptor), IL15RA (receptor for IL15), IL12RB1 (subunit β1 of the IL12 receptor) between these two NK cell subsets, whereas the other chain of the IL12 receptor (IL12RB2, logFC of −2.4, p-value = 7.95E-17 and FDR of 1.06E-13) was found to be significantly downregulated in CD56negCD16pos relative to CD56dimCD16pos NK cells. Significant differences were also observed for IFNGRI (logFC of −1.48, p-value = 2.41E-14 and FDR of 1.19E-11), and both IL18R1 (IL18 receptor, logFC of −3.73, p-value = 4.65E-16 and FDR of 3.35E-13) and IL18RAP (IL18 receptor accessory protein, logFC of −3.7, p-value = 2E-23 and FDR of 6.25E-20). However, IL18BP which encodes the IL18 binding protein is similarly expressed in both CD56negCD16pos and CD56dimCD16pos NK cells (logFC of 0.007). Interestingly, CD122 (IL2RB/IL15RB) appeared to be slightly downregulated in CD56negCD16pos relative to CD56dimCD16pos NK cells (logFC of −0.66, p-value = 4.85E-05 and FDR of 0.001). These observations suggest that CD56negCD16pos may be impervious to activation by IL2, IL12, IL15, and IL18 cytokines.

CD56negCD16pos Cells Do Not Differ From CD56dimCD16pos NK Cells in Cytokine Gene Expression

We assessed the cytokine expression for CD56negCD16pos and CD56dimCD16pos NK cells without any in vitro pre-stimulation (Figure 2B). We did not observe any differences in basal expression levels for IL10, IL15, IL16, IL32, or IFNγ between the two NK subsets. However, we observed that both NK cell subsets expressed high TGFβ levels (logCPM of 10.38) which suggests an inherent anti-inflammatory role.

Validation of Gene Expression by Flow Cytometry

Most of the genes differentially expressed when comparing CD56negCD16pos to CD56dimCD16pos NK cells that are highlighted in the RNA-sequencing experiment have already been described at the protein expression level in previous studies (Forconi et al., 2018; Voigt et al., 2018). CD56dimCD16pos compared to CD56negCD16pos NK cells express less NKP80, IL18Ra, CD161, Nkp46, DNAM1 with no differences for CD57, Perforin 1, CD11c, NKG2D, NKG2C and most of the KIRs. We performed additional flow cytometry experiments and confirmed that CD56dimCD16pos and CD56negCD16pos NK cells cluster separately (Figure 3A). We also confirmed higher expression of IL18Ra, CD62L, DNAM1, and TIM-3 on the CD56dimCD16pos compared to CD56negCD16pos NK cells and higher expression of CD32 and PD-1 on the CD56negCD16pos compared to CD56dimCD16pos NK cells (Figure 4B) but no difference in granzyme B expression, thereby validating our RNAseq results.

Biological Processes Enriched Using gProfiler

Because of the low number of genes differentially expressed between CD56negCD16pos and CD56dimCD16pos NK cells, no gene set enrichment was suitable within the GSEA software. However, using the free online tool gProfiler (Figure 4), we were able to visualize which biological processes were enriched using the 536 significantly differentially expressed genes. The Manhattan plot shows the most significant biological processes involved are immune system processes, leukocyte activation, cell activation, and immune response. These results are consistent with our previous observations that CD56negCD16pos NK cells are activated and should be able to drive cytotoxic responses although through alternative pathways to those commonly used by other NK cell subsets.

DISCUSSION

In this study, we have shown that CD56negCD16pos NK cells share morphological and transcriptional profiles with CD56dimCD16pos NK cells. In fact, CD56negCD16pos cells expressed multiple NK cell markers including KIRs, NKG2C, Nkp30, CD16a, NKG2D, 2B4, CD57, TRAIL, CRTAM and CRACC. Moreover, our previous study highlighted the phenotypic similarities between these two NK cell subsets (Forconi et al., 2018) which was supported by the Voigt et al. proteomic study (Voigt et al., 2018). Together, these findings confirm that CD56negCD16pos cells are true NK cells. However, we find interesting differences between these two NK cell subsets that might impact functional differences and potential targets that may be potentially harnessed therapeutically to drive NK cell-mediated cytotoxicity.
First, we showed that CD56<sup>neg</sup>CD16<sup>pos</sup> cells expressed a unique inhibitory marker profile with higher LILR family and PDCD1 gene expression. LILRB1 encodes for LILRB1 transmembrane receptors which contain 4 ITIMs motif in the cytoplasmic tail and is expressed by various immune cells (Zhang et al., 2015). After stimulation by its ligands, various HLA class
I molecules among others, trigger a strong inhibition signal in order to limit inflammatory and cytotoxic responses. Its most efficient ligand is a dimerized HLA-G which was described as up-regulated in some human tumors such as breast cancer (Lefebvre et al., 2002), certain AML (acute myeloid leukemia) (Kang et al., 2015) and cutaneous T cell lymphoma (Urosevic et al., 2004) in which both CD8$^+$ and CD56$^+$ NKT cells highly expressed LILRB1 and thereby possibly contributed to tumor immune escape. More recently, LILRB1 blockade was shown to enhance cytotoxic CD8$^+$ T cell activity using bispecific T cell engager (BiTE) (Kim et al., 2019) molecules, highlighting the potential of the LILRB1 receptor as an anti-cancer therapeutic target. LILRs are not known to be included in a T cell exhaustion signature (McLane et al., 2019), contrary to other markers such as PD-1, TIM-3, TIGIT, LG3, CTLA-4, KLRG1, BTLA, CD160, and 2B4. In our study, PDCD1, coding for the PD-1 protein, was more highly expressed for CD56$^-$CD16$^+$ relative to CD56$^+$CD16$^+$ NK cells even though its expression was very low compared to most other genes of interest (Figure 2B). At the proteome level, PD-1 was not differentially expressed across NK cell subsets (Voigt et al., 2018). PD-1 is a popular target for immune checkpoint inhibitors, although insufficient in isolation to determine the extent it plays in T cell exhaustion (Blank et al., 2019; McLane et al., 2019). In this viewpoint article, the authors suggested the potential for adaptation of T cells into an exhaustion profile in order to limit immunopathology during chronic infections (Blank et al., 2019). Similarly, we suggest that CD56$^-$CD16$^+$ NK cells are an adaptation of CD56$^+$CD16$^+$ NK cells under conditions of chronic infections or persistent tumor ligand stimulation. In our study of eBL patients, we observed that KLRG1, TIM-3 and CD160 had lower expression in CD56$^-$CD16$^+$ relative to CD56$^+$CD16$^+$ NK cells. Moreover, CTLA-4 and BTLA were not expressed at all, which suggests that the CD56$^-$CD16$^+$ NK subset does not appear to have a more exhausted profile than the other NK cells subsets but they clearly express multiple inhibitory markers which could limit immune responses.

As NK cells function depend on multiple signals triggered by both inhibitory and activation receptors, we assess as well which activation and cytotoxic markers were strongly differentially expressed between CD56$^+$CD16$^+$ and CD56$^-$CD16$^+$ NK cells. Despite numerous markers similarly expressed (CD6, HLA-DR, CD57, CD84, TRAIL, NKp30, NKG2C, NKG2D, 2B4...), CD56$^-$CD16$^+$ NK cells showed a strong downregulation of KLRF1 coding for the cytotoxic receptor NKp80 and to a lesser extent NCR1 coding for NKP46 relative to CD56$^+$CD16$^+$ NK cells. A recent study described NKp80 as a marker of NK cell maturity (Kraft et al., 2016). In brief, they characterized NKp80$^+$ NK cells from secondary lymphoid tissues as stage 4a of NK cell development, which also included low expression of perforin, T-bet, EOMES, lack of Granymes A, B and K but higher expression of RORC2 and AHR (features shared with ILC3). Despite the expression of AHR in both CD56$^+$CD16$^+$ and CD56$^-$CD16$^+$ NK cell subsets, RORC2 was absent and we didn't observe a significant differential expression of T-bet and EOMES genes. However, Perforin 1, granzyme A and B genes appeared to be slightly downregulated within the CD56$^-$CD16$^+$ NK cells. Regarding NKP46, we have previously shown that the expression of this cytotoxic receptor is significantly lower for children exposed to Plasmodium falciparum (Forconi et al., 2018). These data suggest another role for NKP80 and potentially an adaptation of NKP46 expression within eBL children within the context of malaria, EBV co-infections and the eBL pathogenesis. Despite the less expression of cytotoxic receptors essential in natural direct cytotoxicity, NK cells have other ways to kill target cells involving the presence of IgG antibodies. Interestingly, we observed upregulation of low-affinity Fcγ receptor CD16, the medium-affinity Fcγ
FIGURE 5 | Hypothetical model of CD56dimCD16pos and CD56negCD16pos NK cells cytotoxic pathways against both Plasmodium falciparum-infected red blood cells (Pf-iRBC) and endemic Burkitt lymphoma (eBL) tumor cells. (A) Proposed killing pathways used by CD56dimCD16pos NK cells against iRBCs and eBL tumors primarily...
receptor CD32 and Perforin 2 genes within the CD56\textsuperscript{neg}CD16\textsuperscript{pos} compared to the CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cell subset. There are two genes which encode the CD16 protein: FCGR3A and FCGR3B and they share more than 95% of homology so that common CD16 flow cytometry antibodies cannot distinguish them from one another (Ravetch and Perussia, 1989). However, the expression of these two genes were described as cell-specific and with different functions from CD16b which is a glycoposphatidylinositol (GPI) -anchored molecule without intracellular signaling motifs. In order to measure cells specificity of both CD16a and CD16b, Ravetch’s team reconstituted these receptors in transgenic mice (Li et al., 1996). They showed that CD16a is expressed by macrophages and NK cells whereas CD16b is exclusively expressed by neutrophils. In our study we show that CD16a is highly and similarly expressed by CD56\textsuperscript{dim}CD16\textsuperscript{pos} and CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells, however, CD16b is significantly upregulated within CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cell subset. CD16a or FCGR3A receptor is known as an important mediator of antibody dependent cell cytotoxicity (ADCC), an indirect mechanism used by NK cells and other innate immune cells to kill tumors and infected host cells (Hart et al., 2017; Arora et al., 2018; Victor et al., 2018). CD16b has been implicated as an essential mediator of antibody-dependent respiratory burst (ADRB) by neutrophils and has also been shown to be essential for immune complexes (ICs) but not necessarily involved in phagocytosis (Fossati et al., 2002). A recent study showed that CD16b can also regulate ADCC by neutrophils in competition with CD16a (Treffers et al., 2018), and in fact low copy number variation (CNV) of the gene FCG3RB within activated cells might increase ADCC capacity. Our transcriptome analysis was not able to assess CNV although we observed a logCPM of 5.03 for CD16b which is twice less than logCPM of 9.81 for CD16a. It will be important to consider CNV in future experiments in order to clearly determine the role of CD16b within NK cells. Both FCGR2A (CD32a) and FCGR2B (CD32b) were also more highly expressed by CD56\textsuperscript{neg}CD16\textsuperscript{pos} than CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. These findings suggest that CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells may be superior in recognizing antibody opsonized targets. Using recognition of the complement, CD11b and CD18 were found expressed within NK cells from our study population. The heterodimer CD11b/CD18 is called complement receptor 3 (CR3, Mac1 or \(\alpha_M\beta_2\)). CR3 is a multi-functional receptor which was described as predominantly expressed on myeloid and NK cells (Ross and Vetvicka, 1993; Vorup-Jensen and Jensen, 2018) and involved in NK cell cytotoxicity (Lee et al., 2017). CR3 can interact with Fc receptors for adhesion to immune complexes and therefore enhance cell mediated antibody-dependent cytotoxicity (Ortiz-Stern and Rosales, 2003).

Cytokines also play an essential role in NK cell activation and function. In this study we observed a strong significant downregulation of IL18 receptor (IL18RAP and IL18R1) as well as IL12R2B, \(\beta\) chain of IL12 receptor within CD56\textsuperscript{neg}CD16\textsuperscript{pos} relative to CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. IL18 and IL12 are both known to be crucial in NK cell activation, therefore, the downregulation of these receptors on CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells might impair their activation. However, it was previously shown that both IL18 and IL12 receptors are silenced in adaptive CD56\textsuperscript{dim} NK cells in order to block their ability to produce immunoregulatory cytokines (Schlums et al., 2015), whereas the IL15 receptor (IL15RA) is still expressed. We also show that CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells are CD6\textsuperscript{dim}CD103\textsuperscript{−}CD49a\textsuperscript{−}PLZF\textsuperscript{−} with a downregulation of FCER1G (FcR\(\gamma\)y) and SH2D1B (EAT-2). This phenotype has been correlated with a loss of immunoregulatory cytotoxic activity (Schlums et al., 2015). Similar observations were made for HIV-positive individuals who had broadly reactive neutralizing antibodies (bnAbs), lower expression of IL12 and IL18 receptors and PLZF\textsuperscript{−} yet with higher expression of CD6 (Bradley et al., 2018), confirming an adaptive-like NK cell phenotype. In addition, HIV-positive individuals with bnAbs had a higher proportion of CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK, which was associated with better viral control. Interestingly, a positive correlation was observed between CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells and mRNA expression of RAB11FIP5, encoding for Rab11 recycling endosome molecule, which was also found to be increased in CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells from children in our study. Together, these studies support the development of adaptive CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells as adaptation to chronic infections.

In summary, we present a hypothetical model (Figure 5) contrasting killing pathways used by CD56\textsuperscript{dim}CD16\textsuperscript{pos} and CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells against eBL tumor cells as well as P. falciparum-infected red blood cells (iRBC). P. falciparum has been consistently linked to eBL pathogenesis (Moormann and Bailey, 2016). Here, we hypothesize that continual malaria infections induce NK cell adaptation thereby increasing the prevalence of CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells. Figure 5A illustrates how CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells kill iRBC after direct recognition between NKp46 and its putative ligand, P. falciparum erythrocyte membrane protein 1 (PfEMP-1) (Wolf et al., 2017). CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells also use direct recognition to kill tumor cells by activation of multiple receptors. However, KIRs, NKG2A/CD94 and 2B4 can trigger tolerance and therefore allow immune escape of the tumor cells. Determining which NK cell inhibitory ligands are expressed by tumors is an area of ongoing investigation. Finally, in the presence of antibodies directed against iRBCs and tumor cells neo-antigens, CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells can kill both tumor cells and iRBCs through ADCC triggered by CD16a. ADCC against iRBCs has already been well-described by others (Hart et al., 2017; Arora et al., 2018). In contrast, we hypothesize that the main method of killing...
for CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells is through antibody dependent cytotoxicity (Figure 5B). Expression of all CD18/CD11\textsubscript{a/b/c} as well as CD16a, CD16b, CD32a, CD32b and Perforin 2 suggests a multifaceted involvement of antibody opsonization in the killing capacity of CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells. 	extit{P. falciparum} induces a broad range of antibodies directed against the many parasite antigens that are able to trigger ADCC and ADRB (Moormann et al., 2019). Another important component for killing target cells is complement. Present in plasma, iC3b can be fixed on iRBCs as well as tumor cells and thereby opsonize the target for innate cells. This immune complex can be recognized by CR3 expressed on NK cells and trigger complement dependent cell-mediated cytotoxicity (CDCC) against the target cells. Moreover, it was shown that CR3 should be able to communicate with the Fcγ receptors (CD16a/b) and therefore be able to enhance ADCC and ADRB functions (Lee et al., 2017). We therefore suspect that ADCC can as well be important against tumor cells if the tumor is expressing surface antigens for antibody opsonization. In contrast, we and others have shown that CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells are not well-adapted for natural direct cytotoxicity because of their strong downregulation of multiple cytotoxic and activation receptors. Thus, CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cell abundance appears to be a refined adaptation influenced by chronic diseases, that focuses NK cell mediated cytotoxicity toward antibody opsonized targets.

As a limitation of our study, bulk RNA-sequencing didn't allow us to assess the copy number variation (CNV) that can impact the role of CD16b on ADCC. CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells might use other means to kill target cells such as ADRB or CDCC. These pathways will need to be assessed in functional assay in order to determine which cytotoxic mechanisms are engaged by CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study can be found in the NCBI’s database of Genotypes and Phenotypes (dbGaP) with accession number phs1282.V2.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by University of Massachusetts Medical School Institutional Review Board and the Scientific and Ethical Review Unit at the Kenya Medical Research Institute. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

CF designed research, performed research, analyzed data, and wrote the paper. CO designed research, performed research, analyzed data, and reviewed the paper. PO performed research and reviewed the paper. JO contributed to samples acquisition and reviewed the paper. CM reviewed the paper. JB contributed experimental tools, analyzed data, and reviewed the paper. AM designed research, contributed experimental tools, analyzed data, and reviewed the paper.

**FUNDING**

This research was funded by NIH grants: R01 CA189806 and R01 CA134051 (AM).

**ACKNOWLEDGMENTS**

We thank the children and their families for participating in this study. We thank Dr. Rosane B De Oliveira for her help and expertise in cell morphology. This manuscript was approved for publication by the Kenya Medical Research Institute.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2020.00162/full#supplementary-material

**Supplemental Table 1** | Genes significantly differentially expressed between the CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells and CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells (Benjamini-Hochberg procedure (BH) adjusted \(p\)-value < 0.01 and false discovery rate (FDR) < 0.05).

**Supplemental Figure 1** | CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells across population. (A) Representative cytoplots of NK cell subsets repartition from PBMCs within healthy American and Kenyan adults as well as healthy and eBL Kenyan children. CD56\textsuperscript{neg} NK cells are gated in red box and CD66\textsuperscript{a/b} in blue box. (B) Percentage of CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells across our different groups: healthy American, healthy Kenyan, healthy children from Nandi (EBV+/P-), healthy children from Kisumu (EBV+/P+) and eBL children (EBV+/P+). ***Represents a \(p\)-value \(< 0.0001; **represents a \(p\)-value \(< 0.001; ***represents a \(p\)-value \(< 0.01; **represents a \(p\)-value \(< 0.05.

**Supplemental Figure 2** | Excluding NK subsets with possible monocye contamination. Boxplot showing the expression of monocyte associated genes (CD14, CD33, and CD34). We identified one of the sorted CD56\textsuperscript{neg}CD16\textsuperscript{pos} NK cells (highlighted red in the boxplot), to have elevated expression of monocyte marker genes (CD14 and CD33). Elevated expression of these 2 genes could have been due to monocyte contamination during the sorting process of that particular sample. This sample was excluded from all downstream analysis.

**Supplemental Figure 3** | Purity of flow sorted CD56\textsuperscript{neg}CD16\textsuperscript{pos} and CD56\textsuperscript{dim}CD16\textsuperscript{pos} cell subsets. (A) Boxplot of monocyte gene expression profile CD14, CD33, and CD34 genes expression within both CD56\textsuperscript{neg}CD16\textsuperscript{pos} and CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. (B) Boxplot of neutrophil gene expression profile ARG1, ARG1F2, ATI, CA1, CEACAM8, CNTNAP3B, CRISP3, FLT4, ITF1B, ITGAM, ITG2B, LCN2, and MPO genes expression within both CD56\textsuperscript{neg}CD16\textsuperscript{pos} and CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. ***Represents a \(p\)-value \(< 0.0001; **represents a \(p\)-value \(< 0.01.

**Supplemental Figure 4** | Heatmap of all differentially expressed genes for CD56\textsuperscript{neg}CD16\textsuperscript{pos} compared to CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cells. Differential gene expression analysis identified 536 genes to be significantly differentially expressed (Benjamini-Hochberg method [BH] adjusted \(p\)-value < 0.01 and False Discovery Rate (FDR) < 0.05) between the CD56\textsuperscript{neg}CD16\textsuperscript{pos} and the CD56\textsuperscript{dim}CD16\textsuperscript{pos} NK cell subsets. The heatmap shows hierarchical clustering based on the expression profile of the 536 differentially expressed genes between the two NK cell subsets. The color key indicates the intensity associated with normalized expression values. Of the 536 genes identified to be differentially expressed between these two NK cell subsets, 350 genes were downregulated among the CD56\textsuperscript{neg}CD16\textsuperscript{pos} cells compared to the CD56\textsuperscript{neg}CD16\textsuperscript{pos} and 186 genes were upregulated in the CD56\textsuperscript{neg}CD16\textsuperscript{pos} cells compared to the CD56\textsuperscript{dim}CD16\textsuperscript{pos} cells (Supplemental Table 1).
REFERENCES

Andrews, S. (2014). FastQC. A Quality Control Tool for High Throughput Sequence Data. Babraham Bioinformatics. Available online at: http://www.
babraham.ac.uk/projects/fastqc

Arora, G., Hart, G. T., Manzella-Lapeira, J., Doritchamou, J. Y., Narum, D. L., Thomas, L. M., et al. (2018). NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity. Elife 7:e36806. doi: 10.7554/elife.36806

Azzi, T., Lünenmann, A., Murer, A., Ueda, S., Béziat, V., Malmberg, K.-J., et al. (2016). Diversification and Functional Specialization of Human NK Cell Subsets, in Natural Killer Cells Current Topics in Microbiology and Immunology (Basel: Springer), 63–93. doi: 10.1007/978-3-319-38872-9_2

Buckler, G., Maranda, L., Skiles, J., Ong’echa, J. M., Foley, J., Epstein, M., et al. (2016). Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study. Int. J. Cancer. 139, 1231–1240. doi: 10.1002/ijc.31071

Burkitt, D. (1962). A “Tumour Safari” in East and Central Africa. Br. J. Cancer 17, 1779–1788. doi: 10.1038/171779a0

Cham, G. K. K., Turner, L., Lusingu, J., Vestergaard, L., Mmbando, B. P., et al. (2012). Identification of human NK cells that are deficient for signaling adaptor FcRy and specialized for antibody-dependent immune functions. J. Immunol. 184, 6043–6052. doi: 10.4049/jimmunol.1001006

Hu, P. F., Hultin, L. E., Hultin, P., Hausner, M. A., Hirji, K., Jewett, A., et al. (1995). Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD56dimCD56- cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology. 10, 331–340. doi: 10.1097/00014456-199511000-00005

Hwang, I., Zhang, T., Scott, J. M., Kim, A. R., Lee, T., Kakarla, T., et al. (2012). Forconi et al. New Hope for CD56neg NK Cells

J. Exp. Med. 216, 10016–20024. doi: 10.1084/jem.201101681

Herberman, R. B., Nunn, M. E., and Larvin, D. H. (1975). Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 16, 216–229. doi: 10.1002/ijc.2910160204

Horowitz, A., Newman, K. C., Evans, J. H., Korbel, D. S., Davis, D. M., and Riley, E. M. (2010). Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J. Immunol. 184, 894–901. doi: 10.4049/jimmunol.1000106

Hui, P. F., Hultin, L. E., Hu, D., Hausner, M. A., Hirji, K., Jewett, A., et al. (1995). Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD56dimCD56- cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology. 10, 331–340. doi: 10.1097/00014456-199511000-00005

Hwang, I., Zhang, T., Scott, J. M., Kim, A. R., Lee, T., Kakarla, T., et al. (2012). Identification of human NK cells that are deficient for signaling adaptor FcRy and specialized for antibody-dependent immune functions. J. Immunol. 184, 793–802. doi: 10.1038/jimmunol.20120080

Jaksich, G., Michigami, T., and Wiegzell, H. (1975). “Natural” killer cells in the human peripheral blood and their relationship to monoclonal gammopathies of undetermined significance. J. Exp. Med. 141, 1519–1528. doi: 10.1084/jem.141.3.1519

J. Immunol. 157, 387–399.e17. doi: 10.1038/jem.2017015404

Kim, A.-H., et al. (2016). Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. U.S.A. 100, 15011–15016. doi: 10.1073/pnas.2336091100

Kim, A., Han, C.-J., Driver, L., Olow, A., Sewell, A. K., Zhang, Z., et al. (2019). LIR1R1 blockade enhances bisspecific T cell engager antibody-induced tumor cell killing by effector CD8+ T Cells. J. Immunol. 203, 1076–1078. doi: 10.4049/jimmunol.1801472

Kim, A., Han, C.-J., Driver, L., Olow, A., Sewell, A. K., Zhang, Z., et al. (2019). LIR1R1 blockade enhances bisspecific T cell engager antibody-induced tumor cell killing by effector CD8+ T Cells. J. Immunol. 203, 1076–1078. doi: 10.4049/jimmunol.1801472

Kissel, M., Klein, E., and Wiegzell, H. (1975). “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. J. Exp. Med. 146, 1421–1426. doi: 10.1084/jem.183.3.1259

Lee, C.-H., Romain, G., Yan, W., Watanabe, M., Charab, W., Todorova, B., et al. (2017). IgG Fc domains that bind Clq but not effector Fc receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18, 889–898. doi: 10.1038/ni.3770

Lefebvre, S., Antoine, M., Uzan, S., Carosella, E. D., et al. (2018). CD56+ NK cells inhibit antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196, 266–274. doi: 10.1002/jpath.1039

Li, B., and Dewey, C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. doi: 10.1186/1471-2105-12-323

Li, M., Wirthmueller, U., and Ravetch, J. V. (1996). Reconstitution of human Fc gamma RI1 cell type specificity in transgenic mice. J. Exp. Med. 183, 1259–1263. doi: 10.1084/jem.183.3.1259

Long, E. O., Kim, H. S., Liu, D., Peterson, M. E., and Rajagopalan, S. (2013). Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31, 227–258. doi: 10.1146/annurev-immunol-020711-075005

Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10–12. doi: 10.14806/embnet.j.2011.17.200

Mavilio, D., Benjamin, J., Daucher, M., Lombardo, G., Kottilil, S., Planta, M. A., et al. (2003). Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196, 266–274. doi: 10.1002/jpath.1039

Meyers, L., and Babcock, L. (2002). Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196, 266–274. doi: 10.1002/jpath.1039
Whittle, H. C., Brown, J., Marsh, K., Greenwood, B. M., Seidelin, P., Tighe, H., et al. (1984). T-cell control of Epstein-Barr virus-infected B cells is lost during *P. falciparum* malaria. *Nature* 312, 449–450. doi: 10.1038/312449a0

Wolf, A.-S., Sherratt, S., and Riley, E. M. (2017). NK cells: uncertain allies against Malaria. *Front. Immunol.* 8:212. doi: 10.3389/fimmu.2017.00212

Wu, C., Macleod, I., and Su, A. I. (2013). BioGPS and MyGene.info: organizing online, gene-centric information. *Nucleic Acids Res.* 41:D561–D565. doi: 10.1093/nar/gks1114

Zhang, F., Zheng, J., Kang, X., Deng, M., Lu, Z., Kim, J., et al. (2015). Inhibitory leukocyte immunoglobulin-like receptors in cancer development. *Sci. China Life Sci.* 58, 1216–1225. doi: 10.1007/s11427-015-4925-1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Forconi, Oduor, Oluoch, Ong’echa, Münz, Bailey and Moormann.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.